Gary Box

4.5k citations

59 papers · 3.9k · 1 hit paper · h-index 31

Impact in

Oncology top 5%
- Cancer-related Molecular Pathways
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer
- Heat shock proteins research
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways

Papers in

Oncology 23
- Cancer-related Molecular Pathways 11
- CAR-T cell therapy research 5
- Peptidase Inhibition and Analysis 5
Cell Biology 12
- Microtubule and mitosis dynamics 8

Co-authors: Suzanne A. Eccles (28 shared papers)William J. Court (5 shared papers)Peter H. Rhys‐Evans (2 shared papers)Pornchai O‐charoenrat (2 shared papers)Simon P. Robinson (9 shared papers)Melanie R. Valenti (11 shared papers)Helmout Modjtahedi (2 shared papers)Alexis de Haven Brandon (9 shared papers)
Journals: Journal of Medicinal Chemistry (13 papers)Molecular Cancer Therapeutics (6 papers)Cancer Research (5 papers)International Journal of Cancer (4 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United Kingdom Canada United States

In The Last Decade

Gary Box

58 papers receiving 3.7k citations

Gary Box's Hit Papers

align trajectories log scale

The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer 2008 · 681 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2008 Journal of Medicinal Chemistry

Peers

Countries citing papers authored by Gary Box

Since Specialization

Citations

This map shows the geographic impact of Gary Box's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Box with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Box more than expected).

Fields of papers citing papers by Gary Box

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Box. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Box. The network helps show where Gary Box may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Box, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Box Line = papers co-authored together Gary Box links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer Journal of Medicinal Chemistry ·Adrian J. Folkes, Khatereh Ahmadi, Wendy K. ALDERTON, Sonia Alix, Stewart J. Baker, Gary Box, Irina Chuckowree, Paul Andrew Clarke Hit paper breakdown →	2008	681
2	NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis Cancer Research ·Suzanne A. Eccles, Andy Massey, Florence I. Raynaud, Swee Y. Sharp, Gary Box, Melanie R. Valenti, Lisa Patterson, Alexis de Haven Brandon	2008	415
3	Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Molecular Cancer Therapeutics ·Florence I. Raynaud, Suzanne A. Eccles, Sonal K. Patel, Sonia Alix, Gary Box, Irina Chuckowree, Adrian J. Folkes, Sharon M. Gowan	2009	236
4	Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo Cancer Research ·Barbara A. Spruce, Lorna A. Campbell, Niall McTavish, Michelle A. Cooper, M. Virginia L. Appleyard, Mary A. O'Neill, J. W. Howie, Jayne Samson	2004	155
5	Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues Molecular Cancer Therapeutics ·Swee Y. Sharp, Chrisostomos Prodromou, Kathy J. Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung	2007	125
6	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease Nature Chemical Biology ·Trevor C. Dale, Paul Andrew Clarke, Christina Esdar, Dennis Waalboer, Olajumoke Adeniji-Popoola, Maria-Jesus Ortiz-Ruiz, Aurélie Mallinger, Rahul S. Samant	2015	124
7	Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression andin vitro invasion International Journal of Cancer ·Pornchai O‐charoenrat, Peter H. Rhys‐Evans, Helmout Modjtahedi, William J. Court, Gary Box, Suzanne A. Eccles	2000	112
8	CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells Cancer Research ·David Krige, Lindsey A. Needham, Lindsay J. Bawden, Nicolás Flores, Hannah Farmer, Lauren E.C. Miles, Erica Lyn Stone, Juliana Callaghan	2008	104
9	Exploring the Biomechanical Properties of Brain Malignancies and Their Pathologic Determinants In Vivo with Magnetic Resonance Elastography Cancer Research ·Yann Jamin, Jessica K.R. Boult, Jin Li, Sergey Popov, Philippe Garteiser, Jose L. Ulloa, Craig A. Cummings, Gary Box	2015	100
10	In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors Cancer Research ·Swee Y. Sharp, Kathy J. Boxall, Martin Rowlands, Chrisostomos Prodromou, Stephen Mark Roe, Alison Maloney, Marissa V. Powers, Paul Andrew Clarke	2007	95
11	Plexin-B1 mutations in prostate cancer Proceedings of the National Academy of Sciences ·Oscar Gee‐Wan Wong, Tharani Nitkunan, Izumi Oinuma, Chun Zhou, Véronique Blanc, Richard S. Brown, Simon Bott, Joseph Nariculam	2007	79
12	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs Clinical Cancer Research ·Mike I. Walton, Paul D. Eve, Angela Hayes, Melanie R. Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth L. Smith	2012	75
13	Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate Journal of Medicinal Chemistry ·Vassilios Bavetsias, Jonathan M. Large, Chongbo Sun, Nathalie S. Bouloc, Magda N. Kosmopoulou, Mizio Matteucci, Nicola E. Wilsher, Vanessa Martins	2010	74
14	The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 Molecular Cancer Therapeutics ·Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie R. Valenti, Alexis de Haven Brandon, Gary Box, Kathy J. Boxall, G. Wynne Aherne	2010	74
15	Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor Journal of Medicinal Chemistry ·David F. C. Moffat, Sanjay R. Patel, Francesca A. Day, Andrew J. Belfield, Alastair Donald, Martin Rowlands, Judata I. D. Wibawa, Deborah H. Brotherton	2010	74
16	Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia Molecular and Cellular Biology ·Jun Yang, Afshan Ahmed, Evon Poon, Nina P. Perusinghe, Alexis de Haven Brandon, Gary Box, Melanie R. Valenti, Suzanne A. Eccles	2009	73
17	Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases eLife ·Paul Andrew Clarke, Maria-Jesus Ortiz-Ruiz, Robert te Poele, Olajumoke Adeniji-Popoola, Gary Box, Will Court, Stephanie Czasch, Samer El Bawab	2016	71
18	Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen Journal of Medicinal Chemistry ·Aurélie Mallinger, Simon Crumpler, Mark Pichowicz, Dennis Waalboer, Mark Stubbs, Olajumoke Adeniji-Popoola, Bozena Wood, Elizabeth L. Smith	2015	70
19	Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia Journal of Medicinal Chemistry ·Vassilios Bavetsias, Simon Crumpler, Chongbo Sun, Sian Avery, Butrus Atrash, Amir Faisal, Andrew S. Moore, Magda N. Kosmopoulou	2012	66
20	Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands Clinical & Experimental Metastasis ·Pornchai O‐charoenrat, Peter H. Rhys‐Evans, William J. Court, Gary Box, Suzanne A. Eccles	1999	66

About Gary Box

Gary Box is a scholar working on Oncology, Cell Biology, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 59 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (11 papers), Microtubule and mitosis dynamics (8 papers), Protein Degradation and Inhibitors (7 papers), Ubiquitin and proteasome pathways (7 papers), CAR-T cell therapy research (5 papers), Cancer, Hypoxia, and Metabolism (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Oncology (1.0k citations), Molecular Biology (2.6k citations), Genetics (294 citations), Cell Biology (456 citations) and Cancer Research (365 citations). Gary Box has collaborated with scholars based in United Kingdom, Canada and United States. Frequent co-authors include Suzanne A. Eccles, William J. Court, Peter H. Rhys‐Evans, Pornchai O‐charoenrat, Simon P. Robinson, Melanie R. Valenti, Helmout Modjtahedi, Alexis de Haven Brandon, Florence I. Raynaud and Jessica K.R. Boult. Their work appears in journals such as Journal of Medicinal Chemistry, Molecular Cancer Therapeutics, Cancer Research, International Journal of Cancer and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Gary Box

Impact in

Papers in i

In The Last Decade

Gary Box

Gary Box's Hit Papers

Peers

Countries citing papers authored by Gary Box

Fields of papers citing papers by Gary Box

All Works

About Gary Box

Explore authors with similar magnitude of impact

Papers in